BiotechTube

BIW-8962

Phase 1/2Terminated
0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), Mesothelioma

Conditions

Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), Mesothelioma, Phase 2 Portion : Small Cell Lung Cancer(SCLC)

Trial Timeline

Jul 1, 2013 → Jun 1, 2016

NCT ID
NCT01898156

About BIW-8962

BIW-8962 is a phase 1/2 stage product being developed by Kyowa Kirin for Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), Mesothelioma. The current trial status is terminated. This product is registered under clinical trial identifier NCT01898156. Target conditions include Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), Mesothelioma, Phase 2 Portion : Small Cell Lung Cancer(SCLC).

What happened to similar drugs?

7 of 15 similar drugs in Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), Mesothelioma were approved

Approved (7) Terminated (2) Active (6)
✅Lemborexant + PlaceboEisaiApproved
✅progesterone + ProgesteroneMerckApproved
✅NilotinibNovartisApproved
✅NilotinibNovartisApproved
✅NilotinibNovartisApproved
✅AsciminibNovartisApproved
✅DasatinibBristol Myers SquibbApproved

Hype Score Breakdown

Clinical
9
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT01898156Phase 1/2Terminated
NCT00775502Phase 1Terminated

Competing Products

20 competing products in Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), Mesothelioma

See all competitors
ProductCompanyStageHype Score
TERN-701Terns PharmaceuticalsPhase 1/2
36
Tamsulosin HCl + Solifenacin Succinate + EC905Astellas PharmaPhase 1
29
solifenacin succinate + mirabegron + mirabegron/solifenacin succinateAstellas PharmaPhase 1
29
Graceptor®Astellas PharmaPre-clinical
26
Lemborexant + PlaceboEisaiApproved
50
AcalabrutinibAstraZenecaPhase 1/2
36
Sacituzumab tirumotecanMerckPhase 2
42
progesterone + ProgesteroneMerckApproved
39
AsciminibNovartisPre-clinical
30
NilotinibNovartisPhase 3
40
Imatinib mesylateNovartisPhase 3
32
Imatinib Mesylate 600 MG Oral Tablet + Imatinib Mesylate 400 MG Oral Tablet + Imatinib MesylateNovartisPhase 3
32
ribociclib + TrametinibNovartisPhase 1
21
NilotinibNovartisApproved
43
ImatinibNovartisPhase 3
40
NilotinibNovartisApproved
43
GleevecNovartisPhase 2
35
Nilotinib + RuxolitinibNovartisPhase 1/2
32
ABL001NovartisPhase 3
40
asciminibNovartisPhase 2
39